Lupin has announced its second acquisition on the trot – this time an asset purchase deal concerning Temmler Pharma GmbH & Co's specialty product portfolio in Germany.
The deal is expected to buttress Lupin's 2008 acquisition of the German sales and marketing company, Hormosan Pharma.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?